Click Here for 5% Off Your First Aladdin Purchase!

Palbociclib - ≥99%, high purity , Cyclin-dependent kinase 4/cyclin D1 inhibitor, CAS No.571190-30-2, Cyclin-dependent kinase 4/cyclin D1 inhibitor

Specifications & Purity:  ≥99%
Item Number
P126849
Grouped product items
SKUSizeAvailabilityPrice Qty
P126849-10mg
10mg
In stock
$82.90
P126849-50mg
50mg
In stock
$105.90
P126849-100mg
100mg
In stock
$129.90
P126849-500mg
500mg
In stock
$307.90

Potent, highly specific Cdk4/Cdk6\xa0inhibitor

Basic Description

SynonymsPalbociclib|571190-30-2|PD-0332991|Ibrance|PD0332991|PD 0332991|UNII-G9ZF61LE7G|6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one|Palbociclib free base|G9ZF61LE7G|CHEBI:85993|PD 332991|PD-332991|5711
Specifications & Purity≥99%
Storage TempStore at -20°C
Shipped InDry ice
Action TypeINHIBITOR
Mechanism of actionCyclin-dependent kinase 4/cyclin D1 inhibitor

Product Properties

ALogP1.8

Associated Targets

CDK4 Tclin Cyclin-dependent kinase 4 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK2 Tchem Cyclin-dependent kinase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK6 Tclin Cyclin-dependent kinase 6 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CLK4 Tchem Dual specificity protein kinase CLK4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

Pubchem Sid488195370
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488195370
IUPAC Name 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
INCHI InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
InChi Key AHJRHEGDXFFMBM-UHFFFAOYSA-N
Canonical SMILES CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
Isomeric SMILES CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
Alternate CAS 571190-30-2
PubChem CID 5330286
MeSH Entry Terms 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one;Ibrance;palbociclib;PD 0332991;PD-0332991;PD0332991
Molecular Weight 447.53

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

8 results found

Lot NumberCertificate TypeDateItem
D2303098Certificate of AnalysisMar 13, 2023 P126849
D2312478Certificate of AnalysisMar 13, 2023 P126849
D2312486Certificate of AnalysisMar 13, 2023 P126849
D2312487Certificate of AnalysisMar 13, 2023 P126849
D2312488Certificate of AnalysisMar 13, 2023 P126849
D2313084Certificate of AnalysisMar 13, 2023 P126849
D2313087Certificate of AnalysisMar 13, 2023 P126849
D2313097Certificate of AnalysisMar 13, 2023 P126849

Chemical and Physical Properties

SolubilityDMSO

Related Documents

Product Questions

Product Questions

Sign In Hover me Please sign in to submit a question
No questions yet. Be the first to ask the question!

Reviews

Customer Reviews

References

1. Wang L, Wang J, Blaser BW, Duchemin AM, Kusewitt DF, Liu T, Caligiuri MA, Briesewitz R.  (2007)  Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia..  Blood,  110  (6): (2075-83).  [PMID:17537993]
2. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C et al..  (2009)  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro..  Breast Cancer Res,  11  (5): (R77).  [PMID:19874578]
3. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK et al..  (2004)  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts..  Mol Cancer Ther,  (11): (1427-38).  [PMID:15542782]
4. Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T et al..  (2005)  Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6..  J Med Chem,  48  (7): (2388-406).  [PMID:15801831]
5. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M et al..  (2010)  The landscape of somatic copy-number alteration across human cancers..  Nature,  463  (7283): (899-905).  [PMID:20164920]
6. Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn GP, Zhuang L, Rosenbluh J, Chen S, Xiao Y et al..  (2010)  Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM..  Proc Natl Acad Sci USA,  107  (25): (11501-6).  [PMID:20534551]
7. Puyol M, Martín A, Dubus P, Mulero F, Pizcueta P, Khan G, Guerra C, Santamaría D, Barbacid M.  (2010)  A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma..  Cancer Cell,  18  (1): (63-73).  [PMID:20609353]
8. Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES.  (2012)  Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors..  Cell Cycle,  11  (14): (2756-61).  [PMID:22767154]
9. Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer H et al..  (2012)  The requirement for cyclin D function in tumor maintenance..  Cancer Cell,  22  (4): (438-51).  [PMID:23079655]
10. Sawai CM, Freund J, Oh P, Ndiaye-Lobry D, Bretz JC, Strikoudis A, Genesca L, Trimarchi T, Kelliher MA, Clark M et al..  (2012)  Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia..  Cancer Cell,  22  (4): (452-65).  [PMID:23079656]
11. Zhang XH, Cheng Y, Shin JY, Kim JO, Oh JE, Kang JH.  (2013)  A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS..  Cancer Biol Ther,  14  (7): (597-605).  [PMID:23792647]
12. Zanardi E, Bregni G, de Braud F, Di Cosimo S.  (2015)  Better Together: Targeted Combination Therapies in Breast Cancer..  Semin Oncol,  42  (6): (887-95).  [PMID:26615133]
13. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M et al..  (2015)  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study..  Lancet Oncol,  16  (1): (25-35).  [PMID:25524798]
14. Johnston SR.  (2015)  Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways..  J Natl Cancer Inst,  107  (10): (589-97).  [PMID:26251289]
15. Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, Zirkelbach JF, Yu J, Liu Q, Zhao L et al..  (2015)  FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer..  Clin Cancer Res,  21  (21): (4760-6).  [PMID:26324739]
16. Porter B.  (1983)  Primary care pediatrics vs. family practice: a nonissue..  Isr J Med Sci,  19  (8): (736-8).  [PMID:6885367]

Calculator